{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T06:03:41Z","timestamp":1768716221963,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T00:00:00Z","timestamp":1489536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T00:00:00Z","timestamp":1489536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s10928-017-9516-2","type":"journal-article","created":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T14:26:00Z","timestamp":1489587960000},"page":"153-160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Modeling and simulation in dose determination for biodefense products approved under the FDA animal rule"],"prefix":"10.1007","volume":"44","author":[{"given":"Kimberly L.","family":"Bergman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Krudys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. K.","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Florian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,15]]},"reference":[{"key":"9516_CR1","unstructured":"Public health security and bioterrorism preparedness and response act of 2002 (2002), pp 107\u2013188"},{"key":"9516_CR2","unstructured":"Project bioshield act of 2004 (2004), pp 108\u2013276"},{"key":"9516_CR3","unstructured":"U.S. Food and Drug Administration (2002) New drug and biological drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. 21 CFR Parts 314 and 601"},{"key":"9516_CR4","unstructured":"U.S. Food and Drug Administration (2015) Product development under the animal rule: guidance for industry"},{"issue":"4","key":"9516_CR5","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/cpt.172","volume":"98","author":"KL Bergman","year":"2015","unstructured":"Bergman KL (2015) The animal rule: the role of clinical pharmacology in determining an effective dose in humans. Clin Pharmacol Ther 98(4):365\u2013368","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"9516_CR6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/clpt.2009.106","volume":"86","author":"KL Bergman","year":"2009","unstructured":"Bergman KL (2009) The animal rule and emerging infections: the role of clinical pharmacology in determining an effective dose in humans. Clin Pharmacol Ther 86(3):328\u2013331","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"9516_CR7","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1128\/AAC.49.12.5099-5106.2005","volume":"49","author":"MR Deziel","year":"2005","unstructured":"Deziel MR, Heine H, Louie A, Kao M, Byrne WR, Basset J, Miller L, Bush K, Kelly M, Drusano GL (2005) Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. Antimicrob Agents Chemother 49(12):5099\u20135106","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"9516_CR8","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1128\/AAC.00090-06","volume":"50","author":"LM Kao","year":"2006","unstructured":"Kao LM, Bush K, Barnewall R, Estep J, Thalacker FW, Olson PH, Drusano GL, Minton N, Chien S, Hemeryck A, Kelley MF (2006) Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model. Antimicrob Agents Chemother 50(11):3535\u20133542","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"9516_CR9","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.3201\/eid0810.020353","volume":"8","author":"DB Jernigan","year":"2002","unstructured":"Jernigan DB, Raghunathan PL, Bell BP, Brechner R, Bresnitz EA et al (2002) Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 8(10):1019\u20131029","journal-title":"Emerg Infect Dis"},{"issue":"6","key":"9516_CR10","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3201\/eid0706.010604","volume":"7","author":"JA Jernigan","year":"2001","unstructured":"Jernigan JA, Stephens DS, Ashford DA, Omenaca C, Topiel MS, Galbraith M, Tapper M et al (2001) Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 7(6):933\u2013944","journal-title":"Emerg Infect Dis"},{"issue":"47","key":"9516_CR11","first-page":"1049","volume":"50","author":"Centers for Disease Control and Prevention","year":"2001","unstructured":"Centers for Disease Control and Prevention (2001) Update: investigation of bioterrorism-related inhalational anthrax -Connecticut. MMWR Morb Mortal Wkly Rep 50(47):1049\u20131051","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"9516_CR12","doi-asserted-by":"publisher","DOI":"10.3201\/eid2002.130687","author":"KA Hendricks","year":"2014","unstructured":"Hendricks KA, Wright ME, Shadomy SV, Bradley JS, Morrow MG, Pavia AT, Rubinstein E, Holty JE, Messonnier NE, Smith TL et al (2014) Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis. doi:10.3201\/eid2002.130687","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"9516_CR13","first-page":"1","volume":"64","author":"WA Bower","year":"2015","unstructured":"Bower WA, Hendricks K, Pillai S, Guarnizo J, Meaney-Delman D, Centers for Disease Control and Prevention (CDC) (2015) Clinical framework and medical countermeasure use during an anthrax mass-casualty incident\u2014CDC recommendations. MMWR Morb Mortal Wkly Rep 64(4):1\u201321","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"9516_CR14","unstructured":"U.S. Food and Drug Administration (2012) Drugs@FDA drug approval package\u2014raxibacumab clinical pharmacology and biopharmaceutics review. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/125349Orig1s000ClinPharmR.pdf. Accessed 24 Feb 2017"},{"key":"9516_CR15","unstructured":"U.S. Food and Drug Administration (2016) Drugs@FDA drug approval package\u2014anthim clinical pharmacology and biopharmaceutics review. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/125509Orig1s000ClinPharmR.pdf. Accessed 24 Feb 2017"},{"key":"9516_CR16","unstructured":"U.S. Food and Drug Administration (2014) General clinical pharmacology considerations for pediatric studies for drugs and biological products: guidance for industry (draft)"},{"key":"9516_CR17","unstructured":"U.S. Food and Drug Administration (2017) Commentary on non-labeled dosing of oral amoxicillin in adults and pediatrics for post-exposure inhalational anthrax. https:\/\/www.fda.gov\/Drugs\/EmergencyPreparedness\/BioterrorismandDrugPreparedness\/ucm072106.htm. Accessed 24 Feb 2017"},{"issue":"4","key":"9516_CR18","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/sj.clpt.6100126","volume":"81","author":"MA Andrew","year":"2007","unstructured":"Andrew MA, Easterling TR, Carr DB, Shen D, Buchanan ML, Rutherford T, Bennett R, Vicini P, Hebert MF (2007) Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies. Clin Pharmacol Ther 81(4):547\u2013556","journal-title":"Clin Pharmacol Ther"},{"key":"9516_CR19","unstructured":"Centers for Disease Control and Prevention (2010) 2000 CDC growth charts. Accessed 6 June 2016"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-017-9516-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-017-9516-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-017-9516-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T18:21:48Z","timestamp":1684866108000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-017-9516-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,15]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["9516"],"URL":"https:\/\/doi.org\/10.1007\/s10928-017-9516-2","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,15]]},"assertion":[{"value":"31 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical Standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}